Ivabradine
Ivabradine. Selective sinoatrial-node funny-current (If) inhibitor — slows HR without affecting contractility, conduction, or BP. Approved for… Oral half-life 6 h.
Selective sinoatrial-node funny-current (If) inhibitor — slows HR without affecting contractility, conduction, or BP. Approved for heart failure with sinus rhythm + HR ≥ 70 bpm on max β-blocker. Phosphenes (visual brightness) from retinal Ih channel blockade.
PK PROVENANCE, moved here from source_label when that field was shortened to a citation that names the label revision: F ~40% is a secondary/label figure; no primary abstract states an absolute bioavailability for ivabradine. Retained under label provenance rather than deleted, since the resolver default would overstate exposure about twofold. PK: all four values were zero-content on a ST JOHN’S WORT INTERACTION STUDY that reports only peak concentration and exposure, with the half-life given as a direction and no number. The stored ka of 1.4 may collide with that paper "for 14 days" dosing duration, logged as a hypothesis. The 6 h half-life exists only in a systematic review and is retained on that footing. ABSORPTION IS MIXED ZERO- AND FIRST-ORDER, so a single rate constant is structurally wrong: the population model is "a 2-compartment model with mixed 0- and first-order absorption, linked to a 2-compartment model for S18982". THE ACTIVE METABOLITE SPLITS THE EFFECT IN TIME, which no single-analyte model can represent: "the metabolite is responsible for the initial bradycardic effect, whereas the parent compound is responsible for the duration of action". V 100 L dropped as unsourced.
Pharmacokinetics
- Oral — t½ 6 h · F 40%
Sources: PMID:16988208, PMID:26910057, PMID:26265098, PMID:9728900